biotech · Hypertriglyceridemia · Candidiasis, Chronic Mucocutaneous · MTNB
Matinas BioPharma Holdings
Matinas BioPharma Holdings patent portfolio — 8 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Bedminster, USA
- Founded
- 2011
- Employees
- 16
- Programs
- 9
- Drugs
- 5
- Patents
- 8
Matinas BioPharma Holdings patents
8 pharmaceutical patents indexed for Matinas BioPharma Holdings. 0 expire within 24 months.
Matinas BioPharma Holdings has 8 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12409227
Cochleates made with soy phosphatidylserine
granted -
US 11964019
Cochleates made with soy phosphatidylserine
granted -
US 11389407
Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent
granted -
US 11123295
Encholeated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections
granted -
US 10716860
Cochleates made with soy phosphatidylserine
granted -
US 10058521
Omega-3 pentaenoic acid compositions and methods of use
granted -
US 9775907
Cochleates made with soy phosphatidylserine
granted -
US 8906964
Methods of administering compositions comprising docosapentaenoic acid
granted
Frequently asked questions
How many patents does Matinas BioPharma Holdings have?
8 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Matinas BioPharma Holdings patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.